[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100602223":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":10,"centralContacts":33,"locations":39,"responsibleParty":56,"collaborators":10,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":10,"eligibilityCriteria":66,"healthyVolunteers":67,"sex":68,"minAge":69,"maxAge":10,"enrollmentInfo":70,"targetDuration":10,"studyType":73,"phases":10,"briefSummary":74,"conditions":75,"keywords":10,"overallStatus":42,"whyStopped":10,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","OTHER",[8,13,17,20],{"label":9,"type":10,"description":10,"interventionNames":11},"OSAS_chlidren",null,[12],"Procedure: EGR2\u002FNLRP3 pathway activity",{"label":14,"type":10,"description":10,"interventionNames":15},"OSAS_adult",[12,16],"Procedure: fatty tissue",{"label":18,"type":10,"description":10,"interventionNames":19},"non_OSAS_chlidren",[12],{"label":21,"type":10,"description":10,"interventionNames":22},"non_OSAS_adult",[12,16],[24,29],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"PROCEDURE","EGR2\u002FNLRP3 pathway activity","Peripheral blood collection \\& PBMC isolation:\n\nChildren: 3 mL venous blood drawn from the right antecubital vein preoperatively; Adults: 3 mL fasting venous blood drawn the morning after PSG.\n\nCollected in EDTA tubes; PBMCs separated via Ficoll-Paque density gradient. Flow cytometry: 1×10⁶ PBMCs stained for CD14\u002FCD16, HLA-DR, CD11b, CD80\u002FCD86, CD163\u002FCD206.\n\nRNA extraction: Remaining PBMCs lysed in TRIzol and stored at -80 °C for RT-qPCR of EGR2, NLRP3, and downstream genes Serum\u002Fplasma: Within 1 h of collection, centrifuge at 400 × g for 10 min at 4 °C; 1 mL used for ELISA quantification of TNF-α, IL-6, IL-1β, CCL2, IL-17, CRP; remainder stored at -80 °C for future proteomic or metabolomic assays\n\nSaliva sampling \\& processing:\n\n2-3 mL unstimulated saliva expectorated into sterile tubes, kept at 4 °C, processed (centrifuged, aliquoted) within 2 h, then stored at -80 °C.",[14,9,21,18],{"type":25,"name":30,"description":31,"armGroupLabels":32,"otherNames":10},"fatty tissue","Subcutaneous fat biopsy (adults undergoing surgery):\n\n100-200 mg obtained intraoperatively, placed in RNAlater at 4 °C for 24 h, then frozen at -80 °C for downstream RNA-seq, RT-qPCR, and Western blot analyses of EGR2, NLRP3, and related inflammatory markers",[14,21],[34],{"name":35,"role":36,"phone":37,"phoneExt":10,"email":38},"Jiang, PHD,MD","CONTACT","13817719616","jianglaimz@sina.com",[40],{"facility":41,"status":42,"city":43,"state":10,"zip":10,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Shanghai Xinhua hospital","RECRUITING","Shanghai","China","CN",{"type":47,"coordinates":48},"Point",[49,50],121.45806,31.22222,{"lat":50,"lon":49},[53],{"name":54,"role":36,"phone":55,"phoneExt":10,"email":38},"Jiang","+86 13817719616",{"type":57,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Lai Jiang","021-25077820","100602223","egr2-and-nlrp3-pathways-in-obstructive-sleep-apnea-related-cognitive-and-mood-disorders-100602223",false,"NCT07120711","EGR2 and NLRP3 Pathways in Obstructive Sleep Apnea-Related Cognitive and Mood Disorders","Regulatory Mechanisms of EGR2 and NLRP3 Inflammatory Pathways in Cognitive Impairment and Depressive-Anxiety-Like Behaviors Associated With Obstructive Sleep Apnea-Hypopnea Syndrome","Inclusion Criteria:\n\nChildren aged 2-18 years with obstructive snoring or sleep apnea features on initial ENT outpatient screening.\n\nAdults (\\>18 years) with suspected OSAS in a sleep or respiratory clinic, presenting with chronic snoring, witnessed apneas, or daytime sleepiness, and without severe chronic heart, liver, kidney failure, psychiatric disorders, or pregnancy.\n\nSigned written informed consent by the participant or their legal guardian. Not currently enrolled in any other registered clinical trial.\n\nExclusion Criteria:\n\nPresence of congenital craniofacial malformations. Severe heart, lung, liver, or kidney failure, or major neurological disease. Recent use of anti-inflammatory or other immunomodulatory medications. Current psychiatric disorder or pregnancy",true,"ALL","5 Years",{"count":71,"type":72},1000,"ESTIMATED","OBSERVATIONAL","Obstructive sleep apnea-hypopnea syndrome (OSAS) is a common disorder in which repeated airway blockages during sleep lead to low oxygen levels, inflammation, and disrupted sleep. Many OSAS patients-both children and adults-experience problems with memory, attention, and mood, such as anxiety or depression. However, the exact molecular drivers of these brain changes are not fully understood.\n\nThis observational study will enroll:\n\nChildren (ages 2-18) and adults (\\>18 years) with OSAS, as well as age- and sex-matched healthy volunteers.\n\nClinical assessments: Children will undergo routine ENT examinations (including nasal endoscopy and X-rays); adults will have an overnight sleep study (polysomnography). All participants will complete questionnaires on sleepiness (e.g., ESS), mood (PHQ-9, GAD-7), and cognitive screening (MoCA for adults, age-appropriate scales for children).\n\nSample collection: A small blood draw (3 mL) and, when applicable (e.g., adults undergoing surgery), a tiny subcutaneous fat biopsy. Saliva samples will also be collected.\n\nLaboratory tests:\n\nMeasure expression levels of two key inflammatory pathway genes-EGR2 and NLRP3-in blood cells, saliva, and fat tissue using RNA sequencing, RT-qPCR, and Western Blot.\n\nCorrelate these molecular markers with sleep parameters (AHI, oximetry), cognitive scores, and mood scores.\n\nData analysis: Develop and validate machine-learning models that integrate data from multiple tissues to predict who is at highest risk for cognitive or mood disturbances.",[76,77,78],"Obstructive Sleep Apnea-Hypopnea Syndrome","Anxiety Disorders","Depressive Disorders","2025-08-07",{"date":81,"type":82},"2025-08-13","ACTUAL",{"date":84,"type":82},"2025-07-01",{"date":86,"type":72},"2026-09-30",{"name":5,"class":6},1]